Avidity Biosciences Inc (RNA) Stock Price, Quote & News

Company Profile

Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac disea...

Industry: Biotechnology

Sector: Healthcare

Phone: 619 876 0700

Website: atriumtherapeutics.com

Address:

10578 Science Center Drive, Suite 125, San Diego, United States

Arcides Sep. 8 at 4:18 PM

$RNA

0 · Reply

JFais Sep. 8 at 12:37 PM

$NVS the latest pharma to remind us that no one in this sector is immune from biotech "gut punches" Previously paid $12B for $RNA (was a big winner in our Chat for several people including @JoseRestonVA) Shares gapped down 12% (losing $30B in value) after del-desiran failed phase 3 study in DM1 At the least, my takeaway is no matter the high level of due diligence one does (think about ALL the work Novartis did before acquiring the company), biotech landmines are part and part of the sector (drug development is a high-risk endeavor) $XBI

0 · Reply

JFais Sep. 8 at 12:35 PM

0 · Reply

ajmrtxl Aug. 28 at 4:43 PM

$RNA 's latest data on SqueezeFinder

0 · Reply

ajmrtxl Aug. 25 at 4:17 PM

$RNA 's latest squeeze play

0 · Reply

focafoca99 Aug. 21 at 8:33 AM

$RNA gave inducement grants to a new hire under Nasdaq Rule 5635(c)(4).

0 · Reply

focafoca99 Aug. 13 at 9:08 PM

$RNA Atrium Therapeutics announced Q2 2026 financial results.

0 · Reply

STACKD0E Aug. 13 at 12:19 PM

👁 $CADL $RNA $FRMM $QUCY $ONDS

0 · Reply

Quantumup Jul. 23 at 12:03 PM

Cantor🏁 $DYN and said -- We are initiating coverage of Dyne Therapeutics (NASDAQ: DYN) with an Overweight rating. $SRPT CAPR SLDB PTCT $RNA PEPG SNY IONS Here's what else Cantor had to say in its initiation report: https://x.com/Quantumup1/status/2080262413471953360?s=20

0 · Reply

STACKD0E Jul. 21 at 7:02 PM

$RNA ✨️

0 · Reply

Atrium Therapeutics to Participate in Upcoming Investor Conferences

Aug 20, 2026, 6:23 PM EDT - 23 days ago

Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-08-17T07:54:26.000Z - 27 days ago

Atrium Therapeutics earns $15M milestone payment from Bristol Myers

BMY

2026-08-16T14:03:34.000Z - 27 days ago

Atrium Therapeutics reports Q2 EPS ($1.18) vs (75c) last year

Aug 13, 2026, 4:44 PM EDT - 4 weeks ago

Atrium Therapeutics Reports Second Quarter 2026 Financial Results

Aug 13, 2026, 8:00 AM EDT - 4 weeks ago

Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration

BMY

2026-08-06T10:10:23.000Z - 5 weeks ago

Atrium Therapeutics initiated with a Buy at H.C. Wainwright

Jul 20, 2026, 5:58 PM EDT - 7 weeks ago

Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

2026-07-14T10:40:25.000Z - 2 months ago

Atrium Therapeutics announces FDA clearance of ATR 1072 IND application

Jul 14, 2026, 6:30 AM EDT - 2 months ago

Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome

Jul 9, 2026, 1:05 AM EDT - 2 months ago

Atrium Therapeutics Transcript: Transcript

Jul 9, 2026, 12:33 AM EDT - 2 months ago

Atrium Therapeutics Transcript: Transcript

Jul 8, 2026, 10:58 PM EDT - 2 months ago

Atrium Therapeutics Transcript: Transcript

Jul 8, 2026, 5:25 PM EDT - 2 months ago

Atrium Therapeutics Transcript: Transcript

Jul 8, 2026, 5:03 PM EDT - 2 months ago

Atrium Therapeutics Transcript: Transcript

2026-06-18T10:56:05.000Z - 2 months ago

Atrium Therapeutics initiated with an Overweight at Cantor Fitzgerald

2026-06-18T10:12:23.000Z - 2 months ago

Atrium Therapeutics initiated with an Overweight at Cantor Fitzgerald

May 27, 2026, 7:06 AM EDT - 3 months ago

Atrium Therapeutics Transcript: Transcript

2026-05-15T16:48:25.000Z - 4 months ago

Leerink starts ‘interesting preclinical-stage opportunity’ Atrium at Outperform

2026-05-15T10:21:09.000Z - 4 months ago

Atrium Therapeutics initiated with an Outperform at Leerink

May 14, 2026, 4:40 PM EDT - 4 months ago

Atrium Therapeutics Reports First Quarter 2026 Financial Results

2026-04-23T12:11:08.000Z - 4 months ago

Atrium Therapeutics earns $15M development milestone payment from Bristol Myers

BMY

2026-03-10T20:27:36.000Z - 6 months ago

Atrium Therapeutics initiated with an Overweight at Wells Fargo

2026-02-27T14:25:20.000Z - 6 months ago

Atrium Therapeutics launches as newly independent, publicly traded company

NVS

Feb 27, 2026, 9:19 AM EST - 6 months ago

Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies

2026-02-27T14:11:04.000Z - 6 months ago

Novartis completes acquisition of Avidity Biosciences

NVS

2026-02-27T14:07:47.000Z - 6 months ago

Why Is Avidity Biosciences Stock (RNA) Down Today?

NVS

Feb 26, 2026, 4:02 PM EST - 6 months ago

Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Feb 23, 2026, 8:00 AM EST - 6 months ago

Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders

Feb 18, 2026, 5:00 PM EST - 6 months ago

The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1

Feb 2, 2026, 9:44 PM EST - 7 months ago

Avidity Biosciences Announces Expected Record Date for Spin-Off

Jan 28, 2026, 4:15 PM EST - 7 months ago

Sonoma Pharmaceuticals Welcomes New Member of its Board of Directors and New Senior Vice President of Regulatory, Quality and Product Development

SNOA

Jan 15, 2026, 11:35 AM EST - 8 months ago

Pharma sector doubles down on AI amid hopes of slashing costs, timelines

AZN GEHC LLY

Nov 20, 2025, 3:45 PM EST - 9 months ago

These 15 stocks are still showing momentum — and a market-beating edge

BE CIEN CRDO GH INSM LITE MP

Nov 19, 2025, 9:13 AM EST - 9 months ago

Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44

Nov 10, 2025, 4:05 PM EST - 10 months ago

Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights

Oct 27, 2025, 8:05 PM EDT - 10 months ago

Avidity Biosciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Avidity Biosciences, Inc. - RNA

Oct 27, 2025, 12:31 PM EDT - 10 months ago

Why Avidity Biosciences And Dyne Therapeutics Stocks Soared 40% Monday

Oct 27, 2025, 10:22 AM EDT - 10 months ago

Is it too late to buy Avidity stock after Novartis deal?

Oct 27, 2025, 8:16 AM EDT - 10 months ago

Trump's trade deals, Novartis acquires Avidity, Taco Bell's beverage push and more in Morning Squawk

NVS

Oct 27, 2025, 6:29 AM EDT - 10 months ago

Novartis shares slip, Avidity soars after $12 billion biotech deal

NVS

Oct 27, 2025, 4:59 AM EDT - 10 months ago

Novartis Agrees $12 Billion Biotech Deal for Avidity

NVS

Oct 26, 2025, 5:33 PM EDT - 10 months ago

Novartis Agrees to Acquire Avidity Biosciences for $12 Billion

NVS

Oct 26, 2025, 3:46 PM EDT - 10 months ago

Novartis to acquire Avidity Biosciences for about $12B

NVS

Oct 26, 2025, 3:29 PM EDT - 10 months ago

Novartis Deal Values Avidity Biosciences At $12 Billion

NVS

Oct 26, 2025, 1:07 PM EDT - 10 months ago

Novartis to acquire Avidity Biosciences for $12 billion

NVS

Oct 26, 2025, 1:07 PM EDT - 10 months ago

Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG

NVS

Oct 26, 2025, 1:00 PM EDT - 10 months ago

Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline

NVS

Oct 26, 2025, 12:26 PM EDT - 10 months ago

Novartis is in talks to buy U.S. biotech firm Avidity Biosciences for more than $70 a share, Bloomberg News reports

NVS

Oct 26, 2025, 11:09 AM EDT - 10 months ago

Novartis nears $70-plus per share deal to acquire Avidity Biosciences, Bloomberg News reports

NVS

Oct 16, 2025, 9:00 AM EDT - 11 months ago

Avidity Biosciences to Participate in Upcoming Investor Conference

Oct 13, 2025, 9:00 AM EDT - 11 months ago

Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026

Oct 6, 2025, 9:00 AM EDT - 11 months ago

Avidity Biosciences to Present Data from EXPLORE44® Clinical Development Program of Del-Zota in DMD44 at 30th Annual Congress of the World Muscle Society

Sep 15, 2025, 4:01 PM EDT - 12 months ago

Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Sep 11, 2025, 7:56 PM EDT - 1 year ago

Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock

Sep 10, 2025, 4:01 PM EDT - 1 year ago

Avidity Biosciences Announces Proposed Public Offering of Common Stock

Sep 10, 2025, 7:00 AM EDT - 1 year ago

Avidity Biosciences' Del-zota Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in EXPLORE44® and EXPLORE44-OLE™ Phase 1/2 Trial in People Living with DMD44

Aug 27, 2025, 9:00 AM EDT - 1 year ago

Avidity Biosciences to Participate in Upcoming Investor Conferences

Aug 7, 2025, 4:05 PM EDT - 1 year ago

Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights

Aug 6, 2025, 11:41 AM EDT - 1 year ago

Novartis weighs deal for biotech Avidity Biosciences, FT reports

NVS

Jul 28, 2025, 9:00 AM EDT - 1 year ago

Avidity Biosciences Announces Completion of Enrollment for HARBOR™, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory Submission

Jul 23, 2025, 9:00 AM EDT - 1 year ago

Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping

Jun 11, 2025, 9:00 AM EDT - 1 year ago

Avidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD Society International Research Congress

Jun 9, 2025, 7:01 AM EDT - 1 year ago

Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE™ Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants

Jun 9, 2025, 7:00 AM EDT - 1 year ago

Avidity Biosciences Announces the Accelerated Approval Regulatory Pathway in the U.S. is Open for Del-Brax and Initiates the Global, Confirmatory Phase 3 FORWARD™ Study in FSHD

Arcides Sep. 8 at 4:18 PM

$RNA

0 · Reply

JFais Sep. 8 at 12:37 PM

0 · Reply

JFais Sep. 8 at 12:35 PM

0 · Reply

ajmrtxl Aug. 28 at 4:43 PM

$RNA 's latest data on SqueezeFinder

0 · Reply

ajmrtxl Aug. 25 at 4:17 PM

$RNA 's latest squeeze play

0 · Reply

focafoca99 Aug. 21 at 8:33 AM

$RNA gave inducement grants to a new hire under Nasdaq Rule 5635(c)(4).

0 · Reply

focafoca99 Aug. 13 at 9:08 PM

$RNA Atrium Therapeutics announced Q2 2026 financial results.

0 · Reply

STACKD0E Aug. 13 at 12:19 PM

👁 $CADL $RNA $FRMM $QUCY $ONDS

0 · Reply

Quantumup Jul. 23 at 12:03 PM

0 · Reply

STACKD0E Jul. 21 at 7:02 PM

$RNA ✨️

0 · Reply

ajmrtxl Jul. 15 at 1:10 PM

$RNA 's latest data on SqueezeFinder

0 · Reply

dgbio Jul. 15 at 2:03 AM

$RNA Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome. https://investors.atriumtherapeutics.com/2026-07-14-Atrium-Therapeutics-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-ATR-1072-for-Treatment-of-PRKAG2-Syndrome

0 · Reply

STACKD0E Jul. 14 at 9:48 PM

$RNA ✨

0 · Reply

ajmrtxl Jul. 8 at 3:48 PM

$RNA 's latest data on SqueezeFinder

0 · Reply

Vandelay_Industries_Inc Jul. 7 at 6:24 PM

$RNA This one didn't pan out according to the spinoff thesis. It's a non-core position. Breakeven exit to reposition elsewhere. GLTA

0 · Reply

notreload_ai Jun. 18 at 11:53 AM

BofA initiates coverage on $IMMX with a Buy rating and $27 price target. RBC starts $PRAX with Outperform ($449 PT), while Cantor begins coverage on $RNA. Morgan Stanley downgrades $ENGN to Underweight. https://notreload.xyz/xy/bofa-buy-on-immx-rbc-cantor-bullish-on-prax-rna/

0 · Reply

NVDAMillionaire Jun. 10 at 2:00 PM

$RNA Outstanding article that hits the mark on RNA's current state. So if you want to refresh your RNA insights or learn about RNA from scratch, this is a must read. https://everyticker.com/quote/RNA/analysis/atrium-therapeutics-a-270m-bet-on-cardiac-rna-delivery-before-clinical-proof-nasdaq-rna

0 · Reply

d_risk Jun. 2 at 1:15 PM

$RNA - Avidity Biosciences Inc - 10Q - Updated Risk Factors 🚨 Peer Alert: Risk-factor words are +268.9% above peer average (43,350 vs 11,751 across 654 peers). RNA’s updated 10-Q sharpens early-stage and financing risks: newly public, preclinical-only, loss-making, with an unproven cardiac RNA platform, heavy reliance on Avidity and big-pharma partners, growing regulatory/tax burdens, and fresh warnings on internal controls, market volatility, and potential shareholder litigation. #Biotechnology #EarlyStageRisk #PartnershipDependence #RegulatoryChallenges #MarketVolatility 🟢 Added 🟠 Removed https://d-risk.ai/RNA/10-Q/2026-05-14

0 · Reply

SuperGreenToday May. 21 at 10:55 PM

$RNA Share Price: $13.02 Contract Selected: Jan 15, 2027 $20 Calls Buy Zone: $41.65 – $51.45 Target Zone: $68.35 – $83.54 Potential Upside: 55% ROI Time to Expiration: 238 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Vandelay_Industries_Inc May. 15 at 4:35 PM

$RNA ER is fine. No major surprises. Cash burn is reasonable. Stock trades at a 25% discount to cash on balance sheet. Looking forward to 1-2 IND filings in 2H26. Don't see why it shouldn't move higher towards $17+ near term to align with 1x cash.

0 · Reply

focafoca99 May. 14 at 9:18 PM

$RNA launched its Q1 2026 earnings release, reporting results for the quarter ended March 31, 2026.

0 · Reply

Market Cap	11.27B
Revenue (ttm)	10.90M
Net Income (ttm)	-322.30M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,956.88%
Debt to Equity Ratio	0.00

Volume	4,512,920
Avg Vol	2,219,330
Day's Range	N/A - N/A
Shares Out	154.74M
Stochastic %K	64%
Beta	0.93
Analysts	Sell
Price Target	$73.83